Colorectal cancer is a high disease burden cancer and is the second leading cause of cancer deaths worldwide. The first-line treatment option is surgical resection of cancerous tissue. However, the clinical picture becomes more complex for recurrent disease, which occurs in roughly 20% of patients, and a variety of therapies such as adjuvants and immunotherapies have been employed to manage this manifestation of colon cancer. As a result, novel therapeutics are in demand, and a deeper understanding of the tumor microenvironment of colon cancer tissues, such as colon adenocarcinoma, or CAC, is needed.